Table 1 Baseline demographic and clinical characteristics of the samples

Cohort 1

Overall

Control

MCI-AD (Aβ+)

p

 n

52

27

25

 Age

72.13 (5.54)

72.63 (5.38)

71.60 (5.77)

0.509

 Sex, female

25 (48.1)

10 (37.0)

15 (60.0)

0.168

 APOEϵ4 positive

25 (48.1)

6 (22.2)

19 (76.0)

< 0.001

 Education

11.40 (2.97)

11.63 (2.44)

11.16 (3.48)

0.573

 Plasma p-tau217+_Janssen, pg/ml

0.05 (0.04)

0.03 (0.01)

0.08 (0.05)

< 0.001

 Plasma p-tau217_Lilly, pg/ml

0.43 (0.21)

0.31 (0.05)

0.56 (0.23)

< 0.001

Cohort 2

Overall

MCI-AD (Aβ+)

MCI-other Aβ−

MCI-other Aβ+

Stable MCI Aβ−

Stable MCI Aβ+

p across the groups

 n

147

45

24

9

51

18

 Age

72.06 (7.71)

75.89 (6.97)

73.12 (7.60)

71.67 (5.36)

68.84 (7.70)

70.39 (6.70)

< 0.001

 Sex, female

86 (58.5)

34 (75.6)

11 (45.8)

3 (33.3)

29 (56.9)

9 (50.0)

0.042

 APOEϵ4 positive

82 (55.8)

36 (80.0)

11 (45.8)

7 (77.8)

14 (27.5)

14 (77.8)

< 0.001

 MMSE

27.37 (1.78)

26.09 (1.65)

27.00 (1.82)

27.67 (2.06)

28.45 (1.05)

27.83 (1.47)

< 0.001

 Total follow-up, years

4.92 (2.09)

3.66 (1.63)

3.90 (1.97)

4.49 (2.00)

6.34 (1.70)

5.64 (1.65)

< 0.001

 Plasma p-tau217+_Janssen, pg/ml

0.08 (0.07)

0.13 (0.08)

0.05 (0.04)

0.09 (0.07)

0.04 (0.03)

0.07 (0.04)

< 0.001

 Plasma p-tau217_Lilly, pg/ml

0.30 (0.18)

0.46 (0.18)

0.23 (0.11)

0.30 (0.15)

0.20 (0.12)

0.31 (0.11)

< 0.001

 CSF p-tau217+_Janssen, pg/ml

11.66 (16.29)

25.29 (23.38)

4.72 (3.75)

6.61 (3.52)

3.58 (2.38)

12.27 (7.22)

< 0.001

 CSF p-tau217_Lilly, pg/ml

17.83 (22.92)

38.28 (30.62)

8.03 (6.96)

10.02 (4.49)

5.09 (3.26)

19.80 (14.60)

< 0.001